Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1… Read more
Immix Biopharma Inc (IMMX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.715x
Based on the latest financial reports, Immix Biopharma Inc (IMMX) has a cash flow conversion efficiency ratio of -0.715x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.91 Million) by net assets ($8.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immix Biopharma Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Immix Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Immix Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immix Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XinJiang Beiken Energy Engineering Stock Co Ltd
SHE:002828
|
0.068x |
|
Jilin Joinature Polymer Co Ltd
SHG:688716
|
N/A |
|
PT Mayora Indah Tbk
F:D7V
|
0.075x |
|
Daesang Corp
KO:001680
|
0.081x |
|
Gansu Huangtai Wine-marketing Industry Co. Ltd.
SHE:000995
|
0.033x |
|
Climb Global Solutions
NASDAQ:CLMB
|
-0.102x |
|
Anhui Wantong Technology Co Ltd
SHE:002331
|
-0.056x |
|
GBank Financial Holdings Inc. Common Stock
OTCQX:GBFH
|
-0.077x |
Annual Cash Flow Conversion Efficiency for Immix Biopharma Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Immix Biopharma Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.25 Million | $-14.60 Million | -1.101x | -56.94% |
| 2023-12-31 | $16.20 Million | $-11.37 Million | -0.702x | -24.66% |
| 2022-12-31 | $13.16 Million | $-7.41 Million | -0.563x | -537.23% |
| 2021-12-31 | $17.99 Million | $-1.59 Million | -0.088x | -203.27% |
| 2020-12-31 | $-4.73 Million | $-404.69K | 0.086x | -60.52% |
| 2019-12-31 | $-3.65 Million | $-790.03K | 0.217x | -- |